Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced the appointment of Cynthia Collins to the Company’s Board ...

Collins, 66, currently serves as Executive Chair and Interim Chief Executive Officer of Nutcracker Therapeutics, Inc. since February 2025. Her previous roles include CEO positions at Editas Medicine ...

Collins, 66, currently serves as Executive Chair and Interim Chief Executive Officer of Nutcracker Therapeutics, Inc. since February 2025. Her previous roles include CEO positions at Editas ...

Swedish biotech Asgard Therapeutics has brought Shane Olwill on board as chief development officer to help the company’s lead in vivo cell therapy ascend into clinical trials. Release > After ...

Board of directors member, Cynthia Collins, will serve as executive chair Dr. Khandros will remain on the board of Nutcracker Therapeutics EMERYVILLE, Calif.--(BUSINESS WIRE)--Nutcracker Therapeutics, ...

EMERYVILLE, CA, USA I March 26, 2025 I Nutcracker Therapeutics, Inc., a contract, research, development and manufacturing organization (CRDMO) with a next generation RNA precision manufacturing ...

EMERYVILLE, Calif., March 26, 2025--(BUSINESS WIRE)--Nutcracker Therapeutics, Inc., a contract, research, development and manufacturing organization (CRDMO) with a next generation RNA precision ...

Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.